Tirtha Chakraborty

Dr. Tirtha Chakraborty is the Vice President and Head of Research. He specializes in the fields of hematology and genetic engineering. Before joining Vor, Dr. Chakraborty was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first clinical trial for the CRISPR industry. Before that, Dr. Chakraborty was in charge of the synthetic mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis using genetically engineered mouse models in the laboratory of Professor Klaus Rajewsky at the Immune Disease Institute of Harvard Medical School. Dr. Chakraborty’s PhD thesis, completed at the Tata Institute of Fundamental Research in Mumbai, India, was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum.